[{"orgOrder":0,"company":"Univercells","sponsor":"ReiThera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Adenoviral vector-based vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Univercells","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Univercells \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"Univercells \/ Univercells"},{"orgOrder":0,"company":"Univercells","sponsor":"Exyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Univercells","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Univercells \/ Univercells Technologies","highestDevelopmentStatusID":"1","companyTruncated":"Univercells \/ Univercells Technologies"},{"orgOrder":0,"company":"Univercells","sponsor":"Codagenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"COVI-VAC","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Univercells","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Univercells \/ Univercells","highestDevelopmentStatusID":"6","companyTruncated":"Univercells \/ Univercells"},{"orgOrder":0,"company":"Univercells","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BERMUDA","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Univercells","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Univercells \/ Univercells","highestDevelopmentStatusID":"4","companyTruncated":"Univercells \/ Univercells"}]

Find Clinical Drug Pipeline Developments & Deals by Univercells

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Univercells will test a proprietary mRNA vaccine with Altamira’s SemaPhore platform to prevent, treat, and cure diseases across oncology to infectious diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 25, 2024

                          Lead Product(s) : mRNA-based Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Altamira Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Partnership will utilize scale-X™ for Codagenix's pipeline including vaccine candidates for SARS-CoV-2 COVI-VAC™, respiratory syncytial virus (CodaVax™-RSV); influenza (CodaVax™-H1N1); dengue virus; and triple negative breast cancer (using a rati...

                          Brand Name : COVI-VAC

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 20, 2021

                          Lead Product(s) : COVI-VAC

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : Codagenix

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Through this partnership, an integrated plant design combines Exyte’s prefabricated modular construction system, ExyCell, with Univercells Technologies’ NevoLine biomanufacturing platform featuring the scale-X fixed-bed bioreactor at its core.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 14, 2020

                          Lead Product(s) : COVID-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Exyte

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The pan-European consortium of ReiThera, LEUKOCARE and Univercells brings together an adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 23, 2020

                          Lead Product(s) : Adenoviral vector-based vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Recipient : ReiThera

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank